A A AText only | Accessibility | Privacy and cookies

Browse site A to Z

Search results

Go To Advanced Search

You could also try: agreeable (7), pleasant (13), enjoyable (12), lovely (4), nice (245)

Please use your call bell - patient information

Description
We've given you this factsheet because you may be at risk of having a fall in hospital.
Url
/Media/UHS-website-2019/Patientinformation/Visitinghospital/Please-use-your-call-bell-1835-PIL.pdf

G29 Guideline on completion application and study assessment v1 14-10-20...

Description
Guideline on completion of the Sponsorship Application and Study Assessment Introduction According to the UK Policy Framework for Health and Social
Url
/Media/Southampton-Clinical-Research/Downloads/G29-Guideline-on-completion-application-and-study-assessment-v1-14-10-20....pdf

DRD Daratumumab-Lenalidomide-Dexamethasone

Description
Chemotherapy Protocol Myeloma DRD Daratumumab-Lenalidomide-Dexamethasone Regimen • Myeloma – DRD Daratumumab-Lenalidomide-Dexamethasone Indication • Daratumumab in combination with lenalidomide and dexamethasone
Url
/Media/UHS-website-2019/Docs/Chemotherapy-SOPs1/Myeloma/DRD-Daratumumab-Lenalidomide-Dexamethasone.pdf

Sponsor-Request-Form_Jan2020

Description
UHS Sponsorship Application Section 1 – To be completed for all projects requesting UHS to act as Sponsor Study title 1. Propose
Url
/Media/Southampton-Clinical-Research/Downloads/Sponsor-Request-Form-Jan2020.docx

Form_020_Sponsor_Request_Form_v3_03-01-2020

Description
UHS Sponsorship Application Section 1 – To be completed for all projects requesting UHS to act as Sponsor Study title 1. Propose
Url
/Media/Southampton-Clinical-Research/Downloads/Form-020-Sponsor-Request-Form-v3-03-01-2020.docx

DVd-T SC Bortezomib-Daratumumab-Dexamethasone-Thalidomide v1

Description
Details of the Chemotherapy Protocol for Myeloma.
Url
/Media/UHS-website-2019/Docs/Chemotherapy-SOPs1/Myeloma/DVd-T-SC-Bortezomib-Daratumumab-Dexamethasone-Thalidomide.pdf

Isatuximab VRD weekly

Description
Chemotherapy Protocol Myeloma Isa-VRD weekly Isatuximab-Lenalidomide-Bortezomib-Dexamethasone (20) Regimen Myeloma – Isa-VRD weekly Isatuximab-Lenalidomide-Bortezomib-Dexamethasone (20
Url
/Media/UHS-website-2019/Docs/Chemotherapy-SOPs1/Myeloma/Isatuximab-VRD-weekly-Ver1.pdf

MyelomaCTD21CyclophosphamideDexamethasoneThalidomide(CTD)Ver1

Description
Chemotherapy Protocol MULTIPLE MYELOMA CTD (21)-CYCLOPHOSPHAMIDE-DEXAMETHASONE-THALIDOMIDE (21 days) There are multiple versions of this protocol in use. Please
Url
/Media/UHS-website-2019/Docs/Chemotherapy-SOPs1/Myeloma/MyelomaCTD21CyclophosphamideDexamethasoneThalidomideCTDVer1.pdf

Daratumumab SC Ver1

Description
Chemotherapy Protocol Myeloma Daratumumab Subcutaneous Regimen • Myeloma – Daratumumab (SC) Indication • Daratumumab monotherapy is recommended as an option for treating relapsed and
Url
/Media/UHS-website-2019/Docs/Chemotherapy-SOPs1/Myeloma/Daratumumab-SC-Ver1.pdf

Total knee replacement HHFT - patient information

Description
Welcome to your guide to total knee replacement (TKR) surgery.
Url
/Media/UHS-website-2019/Patientinformation/Muscles,jointsandbones/Total-knee-replacement-HHFT-4037-PIL.pdf
1 to 10 of 1000
Previous 1 2 3 4 5 … Next